TrueMe review

Start with what is unusually good. Both weight-loss plans carry the same price at any dose, so holding low costs what it should rather than funding a ladder somebody else is climbing. And each card is headed with its billing cycle, stated as a calendar month. That sounds like nothing until you have priced enough of this category to know how often a "month" turns out to be four weeks — which quietly adds a thirteenth payment to the year — and how rarely a seller simply says which one it means. Prepaying three months takes roughly a quarter off the monthly figure on both plans. Against that, two real limits. The plans are sold as a GLP-1 and a GLP-1/GIP and the molecule appears nowhere on the card, so a reader has to infer what is in the vial from the mechanism named on the label. And coverage is six states, which settles the question for most of the country before any of the pricing applies. The medication is compounded by a licensed third-party pharmacy that is not named, and the company states plainly that it is neither a pharmacy nor a manufacturer.

Vs median

$10/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

TrueMe dispenses through a Not named (licensed third-party pharmacy) facility. No bloodwork is required before you start. A clinician review is included in the price.

TrueMe prices two weight-loss plans before any intake and attaches the clearest pricing language of any seller here to both: "Same Price, Any Dose", against a card headed "Billing cycle — Per month". Both halves of that matter. The first means a low dose is not paying to subsidize a high one. The second is rarer than it should be: four providers here bill a four-week month and call it a month, which quietly adds a thirteenth charge to the year, and TrueMe simply says what its cycle is. Prepaying three months takes each plan down by about a quarter. What it does not do is say what is in the vial. The plans are labeled "GLP-1" and "GLP-1/GIP" and no molecule is named anywhere on the card, so a reader has to infer semaglutide and tirzepatide from the mechanism. And the practical limit is geography rather than price: six states, which rules out most of the country before any of the above applies.

Available in six states only — Texas, Pennsylvania, Colorado, Missouri, Wisconsin and Arizona.

• The plans are sold as "GLP-1" and "GLP-1/GIP" and no molecule is named on the card.
• The dispensing pharmacy is described as a licensed third party but never named.

TrueMe is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Low dose vs full dose
• What a flat price costs at a low dose
• The true annual cost of a plan